The Chief Executive Officer for BetterLife Pharma Inc. (OTCQB:BETRD) (CSE:BETR), an emerging biotechnology company currently preparing its own interferon-based coronavirus treatment clinical trials, recently joined online portal Proactive for a Q&A which included the upcoming merger with Altum Pharmaceuticals, interferon inhalation treatment for COVID-19, what the upcoming trials means for BetterLife, and what advantages AP-003’s interferon alpha2b (IFNa2b) may have over interferon beta treatments.
In the online interview, Dr. Doroudian discusses:
- Why BetterLife plans to kick off its 150 patient Phase 2 clinical trials of the company’s COVID-19 therapeutic AP-003, which uses a nebulizer to deliver the drug directly to the lungs as a fine mist.
- The expectation that the AP-003 Phase 2 trials will be completed in the next three to six months, and subsequent US FDA Emergency Use Authorization
- BetterLife’s agreement with Altum to work towards finalizing a “merger of equals.”
- Recent studies validating interferon as effective against COVID-19 and other respiratory viruses.
- The company’s development of a topical interferon for treatment of human papillomavirus (HPV).
Source: Biospace